SCHEMBL307200

SCHEMBL307200

CCN(CC)CCI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11158256 0.93
SCHEMBL25985028 0.84
SCHEMBL24415184 0.82 KCNH2 (0.37)
SCHEMBL10370166 0.80
SCHEMBL16566151 0.80
SCHEMBL9511602 0.78 SIGMAR1 (0.40)
SCHEMBL23134909 0.78 KDM4E (0.34)
SCHEMBL15897869 0.78
SCHEMBL232247 0.76 MEN1 (0.39)
SCHEMBL15052708 0.76 MEN1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3719012-B1 N-[4-[(2-AMINO-4-PYRIDINYL)OXY]-3-FLUOROPHENYL]-3-(4-FLUOROPHENYL)-1,2,3,4-TETRAHYDRO-2,4-DIOXO-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AS C-MET/AXL INHIBITORS FOR THE TREATMENT OF TUMORS MEDSHINE DISCOVERY INC (CN) 2024-03-06 EP disclosed
CN-112656782-A Methods of treating bacterial infections 尼奥酷里私人有限公司 2021-04-16 CN disclosed
EP-3719012-A1 URACIL COMPOUND AS C-MET/AXL INHIBITOR Medshine Discovery Inc. (CN) 2020-10-07 EP disclosed
US-20180170102-A1 SILYL GROUP-CONTAINING NOVEL COMPOUND, MODIFIED AND CONJUGATED DIENE-BASED POLYMER, AND METHOD FOR PREPARING SAME LG CHEM, LTD. (KR) 2018-06-21 US disclosed
EP-3181136-A1 MICELLE CONTAINING EPIRUBICIN-COMPLEXED BLOCK COPOLYMER AND ANTI-CANCER AGENT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAID MICELLE APPLICABLE TO TREATMENT OF CANCER, RESISTANT CANCER OR METASTATIC CANCER The University of Tokyo (JP) 2017-06-21 EP disclosed
WO-2017053638-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS Graybug Vision, Inc. (US) 2017-03-30 WO disclosed
EP-1957498-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2017-02-15 EP disclosed
EP-1957498-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2017-02-15 EP disclosed
WO-2016164675-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF ARAXES PHARMA LLC (US) 2016-10-13 WO disclosed
US-8329726-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-12-11 US disclosed
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC. 2012-04-05 US disclosed
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC. 2012-04-05 US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 US disclosed
EP-1957498-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING MethylGene Inc. (CA) 2008-08-20 EP disclosed
WO-2008041053-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. (CA) 2008-04-10 WO disclosed
WO-2008041053-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. (CA) 2008-04-10 WO disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
US-3933853-A ANALGESICS, TRANQUILIZERS CLIN MIDY (FR) 1976-01-20 US disclosed